Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance.
J Wight, N Hamad, BA Campbell, M Ku, K Lee, H Rose, T Armytage, M Latimer, HP Lee, ST Lee, M Dickinson, R Khor, E Verner
Intern Med J | Published : 2021
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an ev..View full abstract